
|Videos|July 4, 2022
Dr. Garmezy on the evolving treatment paradigm for progressive urothelial malignancies
Author(s)Urology Times staff
“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.
Advertisement
In this video, Benjamin Garmezy, MD, discusses the expanding armamentarium for the treatment of patients with progressive urothelial malignancies. Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
4
Prof Declan Murphy on interpreting the PROTEUS trial in localized prostate cancer
5











